Startups 2026
Rising Startup
KinCon biolabs GmbH
Innovation & Business Idea
KinCon biolabs patented live-cell conformation reporters transform drug discovery programmes by delivering precise, luminescent readouts of dynamic protein structural changes upon drug binding in native cellular contexts, surpassing binding assays. This captures full-length protein conformations for disease-relevant targets like p53, nuclear receptors and molecular glue-bound E3 ligases, revealing specificity, efficacy, and mechanism-of-action (MoA) to de-risk pipelines.
With pilots underway and first licensing discussions with a top-20 pharma plus CRO partnerships in progress, KinCon biolabs targets market leadership in cellular MoA drug profiling. Scale through co-development deals and reporter licensing, with milestone revenues triggered at clinical-stage entry - enabling pharma's undruggable targets while pursuing VC readiness by 2027 as an optional exit accelerator.
Contact
Eduard Stefan
eduard.stefan@kincon-biolabs.eu
